Holen Sie sich die Stockscreener-App
1.5485
1.87%
0.0285
Schlusskurs vom Vortag:
$1.52
Offen:
$1.5
24-Stunden-Volumen:
29,115
Relative Volume:
0.60
Marktkapitalisierung:
$41.29M
Einnahmen:
$9.06M
Nettoeinkommen (Verlust:
$-50.39M
KGV:
-1.0055
EPS:
-1.54
Netto-Cashflow:
$5.89M
1W Leistung:
-6.72%
1M Leistung:
-10.00%
6M Leistung:
-41.57%
1J Leistung:
+3.93%
1-Tages-Spanne:
$1.50
$1.58
1-Wochen-Bereich:
$1.50
$1.6673
52-Wochen-Spanne:
$1.35
$6.47
Lava Therapeutics Nv Stock (LVTX) Company Profile
Firmenname
Lava Therapeutics Nv
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie LVTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| LVTX | 1.52 | 41.29M | 9.06M | -50.39M | 5.89M | -1.54 |
| VRTX | 450.26 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.54 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.88 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 245.32 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.56 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Lava Therapeutics Nv Stock (LVTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-10-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-19 | Eingeleitet | JP Morgan | Overweight |
| 2021-04-19 | Eingeleitet | Jefferies | Buy |
| 2021-04-19 | Eingeleitet | SVB Leerink | Outperform |
Lava Therapeutics Nv Aktie (LVTX) Neueste Nachrichten
Lava Therapeutics' SWOT analysis: oncology biotech's stock potential amid trials - Investing.com UK
Xinhua News | Portuguese scientists discover new approach to combat Alzheimer's disease - Xinhua
After the Lykos debacle, what’s next for psychedelic therapies? - Pharmaceutical Technology
Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024 - BioSpace
LAVA Therapeutics Announces Appointment of Amy Garabedian as General Counsel and Corporate Secretary - Yahoo Finance UK
LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Yahoo Finance UK
LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference - Yahoo Finance UK
LVTXLAVA Therapeutics N.V. Ordinary Shares Latest Stock News & Market Updates - StockTitan
LAVA Therapeutics (NASDAQ:LVTX) Given Market Outperform Rating at JMP Securities - Defense World
LAVA Therapeutics (NASDAQ:LVTX) Issues Earnings Results - Defense World
LAVA Therapeutics Faces Financial Hurdles - TipRanks
LAVA Reports Second Quarter 2024 Financial Results and Business Update - GlobeNewswire
LAVA Therapeutics NV expected to post a loss of 36 cents a shareEarnings Preview - XM
LAVA Therapeutics (NASDAQ:LVTX) Stock Price Up 2.3% - Defense World
All You Need to Know About LAVA Therapeutics (LVTX) Rating Upgrade to Strong Buy - Yahoo Finance Australia
LAVA Therapeutics (NASDAQ:LVTX) Shares Down 0.7% - American Banking and Market News
LAVA Therapeutics (NASDAQ:LVTX) Trading Down 0.7% - Defense World
Investors in LAVA Therapeutics (NASDAQ:LVTX) from a year ago are still down 16%, even after 44% gain this past week - Yahoo Lifestyle Australia
LAVA Therapeutics (NASDAQ:LVTX) Receives Buy Rating from HC Wainwright - Defense World
Cathie Wood's ARK ETF focuses on PagerDuty, 10X Genomics stock By Investing.com - Investing.com
Lava Therapeutics shares hold target with Buy rating By Investing.com - Investing.com India
Macquarie starts Ensign Group stock coverage with outperform rating By Investing.com - Investing.com India
Barclays sets Charles River Labs stock target with Equalweight rating By Investing.com - Investing.com India
Citi reaffirms sell on Dr. Reddy's shares amid acquisition deal By Investing.com - Investing.com
Jefferies sets buy rating on Syndax stock By Investing.com - Investing.com UK
UBS starts Hydro One stock coverage with neutral rating By Investing.com - Investing.com UK
Lava Therapeutics shares hold target with Buy rating - Investing.com India
JPMorgan starts PagerDuty stock with neutral rating amid 'competitive landscape' By Investing.com - Investing.com Australia
Cava group director Bosserman sells over $2.7 million in company stock By Investing.com - Investing.com Canada
Goldman Sachs sets target on Paramount shares, initiates with sell By Investing.com - Investing.com
Transocean adjusts share capital and treasury shares By Investing.com - Investing.com
LAVA Therapeutics Shareholders Approve Key ResolutionsTipRanks.com - TipRanks
Metric Analysis: LAVA Therapeutics NV (LVTX)'s Key Ratios in the Limelight – DWinneX - The Dwinnex
Kayne Anderson BDC stock gets Market Perform from KBW, notes stable industry focus By Investing.com - Investing.com
Biopharma Layoff Tracker 2024: Barinthus, Agilent, BMS and More Cut Staff - BioSpace
Kinsale Capital's president and COO sells shares worth over $579,000 By Investing.com - Investing.com South Africa
LAVA Announces Annual Meeting of Shareholders - GlobeNewswire
BioCardia secures patent for cardiac delivery catheter By Investing.com - Investing.com India
Karyopharm CEO sells shares worth $3,556 By Investing.com - Investing.com
Finanzdaten der Lava Therapeutics Nv-Aktie (LVTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):